Mr. Bill Jackson reports

VECTOR SCIENCE & THERAPEUTICS CORP. GRANTS OPTIONS AS COMPANY ADVANCES GROWTH STRATEGY

Vector Science and Therapeutics Corp. has approved the grant of 206,610 stock options to certain directors of the company in accordance with the company's stock option plan. The options vest throughout the remainder of 2026, have an exercise price of $1.69 and are exercisable for a period of five years from the date of grant. This grant of the options is subject to the approval of the TSX Venture Exchange.

The company's stock option plan is a 10-per-cent rolling plan. As of the date hereof, a total of 6,556,610 common shares of the company are reserved for issuance under the company's stock option plan, with 8,792,446 options remaining for issuance.

About Vector Science and Therapeutics Inc.

Vector Science, headquartered in Mequon, Wis., develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions where precision matters and systemic risks are unacceptable.